Adverse Drug Events Reporting News

• Popular Joint Supplement Cuts Nephropathy Risk in T2D People with type 2 diabetes who regularly use the supplement glucosamine have a lower risk for microvascular complications and diabetic nephropathy, a prospective observational study finds.
  Medscape Medical News, April 11, 2025
• Alert NICE Backs Oral Drug for Advanced Bladder Cancer NICE has approved the oral drug erdafitinib for adults with advanced urothelial cancer and FGFR3 alterations, offering new hope and home-based treatment.
  Medscape News UK, April 10, 2025
• Methylene Blue: Miracle Cure or Dangerous Trend? As influencers tout methylene blue as a cognitive enhancer and anti-aging solution, experts caution about its serious risks and lack of evidence.
  Medscape Medical News, April 10, 2025
• AAN 2025 Inebilizumab Effective Up to 52 Weeks in Myasthenia Gravis Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with generalized myasthenia gravis, a phase 3 trial suggests.
  Medscape Medical News, April 10, 2025
• Cardiac Dysfunction Surfaces Early With Cancer Treatment Cardiac problems associated with vascular endothelial growth factor inhibitors occur frequently in patients with cancer.
  Medscape Medical News, April 10, 2025
• Experts Push Back on RFK Jr’s Infection Comments The new Secretary of Health and Human Services has made claims about measles and other communicable diseases that could lead to sickness, and even death, his critics claim.
  Medscape Medical News, April 09, 2025
• Infections Higher With JAK Inhibitors in Eczema Study A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.
  Medscape Medical News, April 09, 2025
• GMALL Protocol in Rare Lymphoma: The Good, Bad, and Toxic German study shows GMALL protocol is effective yet highly toxic in treating Burkitt lymphoma in adults.
  Medscape Medical News, April 08, 2025
• Do Low-Grade Toxicities Affect Melanoma Treatment Success? The burden of low-grade toxicity is clinically significant in patients treated with adjuvant pembrolizumab for stage III melanoma.
  Medscape Medical News, April 08, 2025
• Benznidazole Provides Long-Term Efficacy in Chagas Disease Benznidazole shows better efficacy than posaconazole in patients with chronic Chagas disease, a long-term follow-up study shows.
  Medscape News UK, April 07, 2025
• What Else Can GLP-1 Drugs Do for Your Patients? How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, and neurological diseases.
  Medscape Medical News, April 07, 2025
• Colombia to Columbia: A Quest for Better Myeloma Outcomes Hematologist-oncologist Mateo Mejia Saldarriaga, MD, combines clinical care with research aimed at helping patients with treatment-resistant multiple myeloma.
  Medscape Medical News, April 04, 2025
• Esketamine Combo Bests SSRIs for TRD in Head-to-Head Trial Treatment with esketamine combined with an SNRI is linked to fewer adverse outcomes than treatment with an SSRI alone.
  Medscape Medical News, April 04, 2025
• Cenobamate May Cut Seizures in Drug-Resistant Epilepsy A real-world study supports cenobamate as an effective option for patients with drug-resistant epilepsy even after multiple treatment failures.
  Medscape News UK, April 02, 2025
• Stop Smoking Drugs Don’t Promote Congenital Malformations Large retrospective study supports benefits of quitting with smoking cessation medications over risks of smoking.
  Medscape Medical News, April 02, 2025
• Multiple Drug Initiations Common Despite Limited Evidence A recent study shows that primary care physicians often initiate multiple medications simultaneously despite limited supporting evidence, with notable variations across prescribers and institutions.
  Medscape Medical News, April 02, 2025
• ELCC 2025 Skin Care Regimen Cuts Toxicities of Combo NSCLC Therapy A preventative and proactive dermatologic regimen reduces skin and nail adverse reactions in patients with EGFR-mutant NSCLC receiving first-line treatment with amivantamab plus lazertinib.
  Medscape Medical News, April 01, 2025
• ELCC 2025 Subcutaneous Pembro vs IV in NSCLC Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy and safety profile with IV pembrolizumab.
  Medscape Medical News, March 31, 2025
• Gene Tests Could Prevent Avoidable Adverse Drug Reactions A UK study found that nearly 1 in 10 adverse drug reactions involve medications influenced by genetic factors, highlighting the need for wider testing.
  Medscape News UK, March 28, 2025
• CLL: Pirtobrutinib’s Star Turn May Get an Encore New data could turn third-line treatment into an earlier therapy.
  Medscape Medical News, March 28, 2025